Korro Bio vs Korsana Biosciences
Korro Bio is the larger business, with $6.4m of revenue in fiscal 2025 against $2.1m for Korsana Biosciences (3.1 times as much). Korro Bio grew faster (181.5% against 3.7%). Korsana Biosciences kept more of each dollar of sales as profit: a net margin of -170.1% against -1834.5%.
| Latest fiscal year | Korro BioKRRO, 2025 | Korsana BiosciencesKRSA, 2025 |
|---|---|---|
| Revenue | $6.4m | $2.1m |
| Revenue growth | 181.5% | 3.7% |
| Net income | −$117m | −$3.5m |
| Operating margin | — | -239.8% |
| Net margin | -1834.5% | -170.1% |
| Return on equity | -110.7% | -39.3% |
| Free cash flow | −$79.1m | −$3.3m |
| Cash | $21.8m | $3.2m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 58 | — |
| Market value | $233m | $135m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 16 buys, 33 sales | 0 buys, 0 sales |